BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 21.5] [Reference Citation Analysis]
Number Citing Articles
1 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
2 Jeon HL, Kim SC, Park SH, Shin JY. The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea. Semin Arthritis Rheum 2021;51:989-95. [PMID: 34403814 DOI: 10.1016/j.semarthrit.2021.07.004] [Reference Citation Analysis]
3 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
4 Kim SE, Park JW, Kim HS, Jang MK, Suk KT, Kim DJ. The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. Int J Mol Sci 2021;22:11680. [PMID: 34769109 DOI: 10.3390/ijms222111680] [Reference Citation Analysis]
5 Tan HK, Teng MLP, Soh AYS, Cheo SHY, Fook-Chong S, Goh GBB, Tan CK, Wong GW, Lee GH, Chang JPE. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites. Am J Gastroenterol 2021;116:1437-46. [PMID: 33834737 DOI: 10.14309/ajg.0000000000001176] [Reference Citation Analysis]
6 Mari A, Khoury T, Said Ahmad H, Abu Baker F, Kadah A, Sbeit W, Pellicano R, Mahamid M. The association between non-alcoholic fatty liver disease and valvular heart disease. Minerva Cardioangiol 2020;68:42-6. [PMID: 31789009 DOI: 10.23736/S0026-4725.19.05087-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ning L, Liu R, Lou X, Du H, Chen W, Zhang F, Li S, Chen X, Xu G. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2019;31:735-42. [DOI: 10.1097/meg.0000000000001398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
8 Li H, Xu QY, Xie Y, Luo JJ, Cao HX, Pan Q. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis. Ann Hepatol. 2021;24:100316. [PMID: 33515803 DOI: 10.1016/j.aohep.2021.100316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Siddiqui ATS, Parkash O, Hashmi SA. Malnutrition and liver disease in a developing country. World J Gastroenterol 2021; 27(30): 4985-4998 [PMID: 34497430 DOI: 10.3748/wjg.v27.i30.4985] [Reference Citation Analysis]
10 Hu X, Yu W, Yang L, Pan W, Xu K, Chen X, Li Q, Zhang Y, Chen G, Wen J, Gu X, Zhang X. First-degree family history of diabetes is associated with nonalcoholic fatty liver disease independent of glucose metabolic status. J Diabetes Complications 2022;36:108083. [PMID: 34840086 DOI: 10.1016/j.jdiacomp.2021.108083] [Reference Citation Analysis]
11 Itoh M, Ogawa Y, Suganami T. Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver. Nagoya J Med Sci 2020;82:391-7. [PMID: 33132423 DOI: 10.18999/nagjms.82.3.391] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol 2019;54:1096-105. [PMID: 31134334 DOI: 10.1007/s00535-019-01594-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Abassa K, Wu X, Xiao X, Zhou H, Guo Y, Wu B. Effect of alcohol on clinical complications of hepatitis virus-induced liver cirrhosis: a consecutive ten-year study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02198-w] [Reference Citation Analysis]
14 Liang Y, Zhou S, Chen X, Yu L, Zhang D, Lin C. Gut Microbiome and Nonalcoholic Fatty Liver Disease (NAFLD): Implications for Nursing Care of Individuals Living With Chronic Metabolic Diseases. Gastroenterol Nurs 2021;44:E18-22. [PMID: 33538526 DOI: 10.1097/SGA.0000000000000545] [Reference Citation Analysis]
15 Ji Y, Liang Y, Mak JC, Ip MS. Obstructive sleep apnea, intermittent hypoxia and non-alcoholic fatty liver disease. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.04.006] [Reference Citation Analysis]
16 Zhang C, Wu Y, Yuan S, Dou X, Sheng Q, Wang J, Tian W, Yao L, Ding Y. Characteristics of Drug-Induced Liver Injury in Northeast China: Disease Spectrum and Drug Types. Dig Dis Sci 2020;65:3360-8. [PMID: 31907771 DOI: 10.1007/s10620-019-06030-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Licata A, Zerbo M, Como S, Cammilleri M, Soresi M, Montalto G, Giannitrapani L. The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement? Nutrients 2021;13:4014. [PMID: 34836267 DOI: 10.3390/nu13114014] [Reference Citation Analysis]
18 Zhu W, Wang L, Zhao X, Wang T, Shi X, Ou X, Wang Y, Wang X, Duan W, Wang Q, Jia J, Ma H. Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug‐induced liver injury. Hepatol Res 2020;50:224-32. [DOI: 10.1111/hepr.13435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liou BH, Sun HY, Yang CJ, Syue LS, Lee YL, Tang HJ, Tsai HC, Lin CY, Chen TC, Lee CY, Huang SH, Liu CW, Lu PL, Lin SP, Wang NC, Cheng A, Ko WC, Cheng SH, Hung CC; Taiwan HIV Study Group. Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study. Infect Dis Ther 2021;10:827-38. [PMID: 33733316 DOI: 10.1007/s40121-021-00424-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
21 Newman LA, Muller K, Rowland A. Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04256-8] [Reference Citation Analysis]
22 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
23 Lin ZL, Ding J, Sun GP, Li D, He SS, Liang XF, Huang XR, Xie J. Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy. Curr Med Sci 2020;40:145-54. [PMID: 32166677 DOI: 10.1007/s11596-020-2158-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep 2021;3:100324. [PMID: 34381984 DOI: 10.1016/j.jhepr.2021.100324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Iliaz R, Yuce T, Torun S, Cavus B, Gulluoglu M, Bozaci M, Karaca C, Akyuz F, Demir K, Besisik F, Kaymakoglu S. Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis. Eur J Gastroenterol Hepatol 2019;31:1247-9. [PMID: 30913053 DOI: 10.1097/MEG.0000000000001406] [Reference Citation Analysis]
26 Nouri-Vaskeh M, Malek Mahdavi A, Afshan H, Alizadeh L, Zarei M. Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial. Phytother Res 2020;34:1446-54. [PMID: 32017253 DOI: 10.1002/ptr.6620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, Zhang L, Chen P, Wang S, Lao XQ, Tse LA, Xu W, Zheng ZJ, Wong MCS. Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis. Liver Cancer 2021;10:330-45. [PMID: 34414121 DOI: 10.1159/000515304] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Farooqui N, Elhence A, Shalimar. A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2022;12:155-73. [DOI: 10.1016/j.jceh.2021.08.017] [Reference Citation Analysis]
29 van Dijk AM, Dingerink S, Chilunga FP, Meeks KAC, Bahendeka S, Schulze MB, Danquah I, Osei TB, Serné E, Agyemang C, Holleboom AG. Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. J Clin Transl Hepatol 2021;9:494-502. [PMID: 34447678 DOI: 10.14218/JCTH.2021.00066] [Reference Citation Analysis]
30 Zheng J, Xia Z, Xu Y, Ou Z, Lin X, Jin S, Liu Y, Wu J. Identification of novel hepatitis B virus therapeutic vaccine candidates derived from polymerase protein. Aging (Albany NY) 2021;13:14372-84. [PMID: 34016795 DOI: 10.18632/aging.203053] [Reference Citation Analysis]
31 Lu S, Zhang J, Lin S, Zheng D, Shen Y, Qin J, Li Y, Wang S. Recent advances in the development of in vitro liver models for hepatotoxicity testing. Bio-des Manuf 2021;4:717-34. [DOI: 10.1007/s42242-021-00142-7] [Reference Citation Analysis]
32 Lin S, Wang M, Liu Y, Huang J, Wu Y, Zhu Y, Wang X. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45:101483. [PMID: 32646847 DOI: 10.1016/j.clinre.2020.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Chen CW, Cheng JS, Chen TD, Le PH, Ku HP, Chang ML. The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts. Therap Adv Gastroenterol 2019;12:1756284819855732. [PMID: 31244896 DOI: 10.1177/1756284819855732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Soresi M, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R, Terranova A, Lazzaro LA, Emma MR, Augello G, Cervello M, Pantuso G, Montalto G, Giannitrapani L. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.Biomed Res Int. 2020;2020:5023157. [PMID: 32420347 DOI: 10.1155/2020/5023157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xu HY, Ren JH, Su Y, Ren F, Zhou YJ, Jiang H, Cheng ST, Zhang CR, Chen J. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim. J Ethnopharmacol 2020;257:112787. [PMID: 32224198 DOI: 10.1016/j.jep.2020.112787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
37 Charatcharoenwitthaya P, Liangpunsakul S, Piratvisuth T. Alcohol-Associated Liver Disease: East Versus West. Clin Liver Dis (Hoboken) 2020;16:231-5. [PMID: 33489093 DOI: 10.1002/cld.920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bakhshipour A, Sargolzaie N, Rafaiee R. Status of Immunity Against the Hepatitis A Virus in Healthy Population: A Report From Southeastern Iran. Arch Clin Infect Dis 2021;16. [DOI: 10.5812/archcid.118869] [Reference Citation Analysis]
39 Lubel JS, Roberts SK, Howell J, Ward J, Shackel NA. Current issues in the prevalence, diagnosis and management of hepatocellular carcinoma in Australia. Intern Med J 2021;51:181-8. [DOI: 10.1111/imj.15184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Godfrey E, Desai M, Lam F, Goss J, Rana A, Miloh T. Higher Waitlist Mortality in Pediatric Acute-on-chronic Liver Failure in the UNOS Database. J Pediatr Gastroenterol Nutr 2021;72:80-7. [PMID: 32796428 DOI: 10.1097/MPG.0000000000002891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Chen DY, Lin CH, Chen HH, Tang KT. Association of tumor necrosis factor-α inhibitors and liver cirrhosis in patients with rheumatoid arthritis: A nationwide population-based nested case-control study. Int J Rheum Dis 2022. [PMID: 34994523 DOI: 10.1111/1756-185X.14272] [Reference Citation Analysis]
42 Kim JM, Kim DG, Kim J, Lee K, Lee KW, Ryu JH, Kim BW, Choi DL, You YK, Kim DS, Nah YW, Kang KJ, Cho JY, Hong G, Yu HC, Moon JI, Choi D, Hwang S, Kim MS. Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry. Clin Mol Hepatol 2021;27:451-62. [PMID: 33525077 DOI: 10.3350/cmh.2020.0292] [Reference Citation Analysis]
43 Wu J, Meng QH. Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease. World J Gastroenterol 2020; 26(31): 4567-4578 [PMID: 32884217 DOI: 10.3748/wjg.v26.i31.4567] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int 2021. [PMID: 34687130 DOI: 10.1111/liv.15085] [Reference Citation Analysis]
45 Lim SL, Johal J, Ong KW, Han CY, Chan YH, Lee YM, Loo WM. Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial. JMIR Mhealth Uhealth 2020;8:e14802. [PMID: 32281943 DOI: 10.2196/14802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
46 Li B, Huang H, Huang R, Zhang W, Zhou G, Wu Z, Lv C, Han X, Jiang L, Li Y, Li B, Zhang Z. SEPT9 Gene Methylation as a Noninvasive Marker for Hepatocellular Carcinoma. Dis Markers 2020;2020:6289063. [PMID: 33178361 DOI: 10.1155/2020/6289063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Chan KH, Bennett DA, Kurmi OP, Yang L, Chen Y, Lv J, Guo Y, Bian Z, Yu C, Chen X, Dong C, Li L, Chen Z, Lam KBH; China Kadoorie Biobank Study Group. Solid fuels for cooking and tobacco use and risk of major chronic liver disease mortality: a prospective cohort study of 0.5 million Chinese adults. Int J Epidemiol 2020;49:45-55. [PMID: 31650183 DOI: 10.1093/ije/dyz216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Shoraka S, Mohebbi SR, Hosseini SM, Asadzadeh Aghdaei H, Zali MR. Identification of plasma lncRNA-ATB levels in hepatitis B virus-related cirrhosis and non-cirrhotic chronic hepatitis B patients. Virus Res 2021;303:198503. [PMID: 34331990 DOI: 10.1016/j.virusres.2021.198503] [Reference Citation Analysis]
49 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
50 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
51 van Hunsel F, van de Koppel S, Skalli S, Kuemmerle A, Teng L, Wang JB, Barnes J. Analysis of Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected ADR Database Vigibase. Front Pharmacol 2019;10:1326. [PMID: 31780942 DOI: 10.3389/fphar.2019.01326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
52 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 34.0] [Reference Citation Analysis]
53 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Meng D, Wei Y, Feng X, Kang B, Wang X, Qi J, Zhao X, Zhu Q. CT-Based Radiomics Score Can Accurately Predict Esophageal Variceal Rebleeding in Cirrhotic Patients. Front Med (Lausanne) 2021;8:745931. [PMID: 34805214 DOI: 10.3389/fmed.2021.745931] [Reference Citation Analysis]
55 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Xu W, Liu F, Shen X, Li R. Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. J Hepatocell Carcinoma 2020;7:233-56. [PMID: 33154956 DOI: 10.2147/JHC.S271498] [Reference Citation Analysis]
57 Jun BG, Kim M, Shin HS, Yi J, Yi S. Impact of overweight and obesity on the risk of hepatocellular carcinoma: a prospective cohort study in 14.3 million Koreans. Br J Cancer. [DOI: 10.1038/s41416-022-01771-0] [Reference Citation Analysis]
58 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
59 Ni Y, Xu Z, Li C, Zhu Y, Liu R, Zhang F, Chang H, Li M, Sheng L, Li Z, Hou M, Chen L, You H, McManus DP, Hu W, Duan Y, Liu Y, Ji M. Therapeutic inhibition of miR-802 protects against obesity through AMPK-mediated regulation of hepatic lipid metabolism. Theranostics 2021;11:1079-99. [PMID: 33391522 DOI: 10.7150/thno.49354] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Kakuda TN, Yogaratnam JZ, Westland C, Gane EJ, Schwabe C, Vuong J, Patel M, Snoeys J, Talloen W, Lenz O, Fry J, Chanda S, van Remoortere P. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral Therapy 2021;26:13-24. [DOI: 10.1177/13596535211044331] [Reference Citation Analysis]
61 Wang WJ, Xiao P, Xu HQ, Niu JQ, Gao YH. Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol 2019; 25(12): 1445-1456 [PMID: 30948908 DOI: 10.3748/wjg.v25.i12.1445] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
62 Kurosaki K, Uesawa Y. Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions. Biomolecules 2021;11:944. [PMID: 34202146 DOI: 10.3390/biom11070944] [Reference Citation Analysis]
63 Zhang H, Yang X, Zhu L, Li Z, Zuo P, Wang P, Feng J, Mi Y, Zhang C, Xu Y, Jin G, Zhang J, Ye H. ASPM promotes hepatocellular carcinoma progression by activating Wnt/β-catenin signaling through antagonizing autophagy-mediated Dvl2 degradation. FEBS Open Bio 2021;11:2784-99. [PMID: 34428354 DOI: 10.1002/2211-5463.13278] [Reference Citation Analysis]
64 Cao R, Zhang S, Li J, Zhang J, Zhao Y, Jiao P, Wang C, Guo Z. Chinese Herbal Medicine-Induced Rapid Liver Cirrhosis: A Case Report. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.118934] [Reference Citation Analysis]
65 Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. GSK-3 in liver diseases: Friend or foe? Biochim Biophys Acta Mol Cell Res 2020;1867:118743. [PMID: 32417256 DOI: 10.1016/j.bbamcr.2020.118743] [Reference Citation Analysis]
66 Nam JY, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Bae SH, Ki M, Choi HY, Lee EY, Jeong SH. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. Gut Liver 2020;14:207-17. [PMID: 31158950 DOI: 10.5009/gnl19005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
67 Mishra D, Dash KR, Khatua C, Panigrahi S, Parida PK, Behera SK, Barik RK, Pradhan S, Sahu SK, Thakur B, Singh SP. A Study on the Temporal Trends in the Etiology of Cirrhosis of Liver in Coastal Eastern Odisha. Euroasian J Hepatogastroenterol 2020;10:1-6. [PMID: 32742964 DOI: 10.5005/jp-journals-10018-1312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Zhou S, Li Y, Gao J, Wang Y, Ma X, Ding H, Li X, Sun S. Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. Bioengineered 2022;13:2851-65. [PMID: 35037840 DOI: 10.1080/21655979.2021.2024957] [Reference Citation Analysis]
69 Wang H, Gao P, Chen W, Yuan Q, Lv M, Bai S, Wu J. A cross-sectional study of alcohol consumption and alcoholic liver disease in Beijing: based on 74,998 community residents. BMC Public Health 2022;22:723. [PMID: 35410318 DOI: 10.1186/s12889-022-13175-z] [Reference Citation Analysis]
70 Hsieh MS, Cheng KC, Hsieh ML, Chiang JH, Hsieh VC. Mortality Risk and Decompensation in Hospitalized Patients with Non-Alcoholic Liver Cirrhosis: Implications for Disease Management. Int J Environ Res Public Health 2021;18:E606. [PMID: 33445719 DOI: 10.3390/ijerph18020606] [Reference Citation Analysis]
71 Fromenty B. Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis. Liver Research 2019;3:157-69. [DOI: 10.1016/j.livres.2019.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Liu W, Zhang F, Quan B, Li M, Lu S, Li J, Chen R, Yin X. The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Dis Markers 2021;2021:3514827. [PMID: 34840628 DOI: 10.1155/2021/3514827] [Reference Citation Analysis]
73 Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng C, Sengupta S, Mostafid H, Kamat AM, Black PC, Shariat S, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. European Urology 2020;78:893-906. [DOI: 10.1016/j.eururo.2020.09.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
74 Chen W, Jiang J, Gong L, Shu Z, Xiang D, Zhang X, Bi K, Diao H. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis. J Exp Clin Cancer Res 2021;40:1. [PMID: 33390177 DOI: 10.1186/s13046-020-01803-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
75 Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70:1119-1133. [PMID: 31070259 DOI: 10.1002/hep.30702] [Cited by in Crossref: 88] [Cited by in F6Publishing: 101] [Article Influence: 44.0] [Reference Citation Analysis]
76 Hao X, Chen Y, Bai L, Wei H, Sun R, Tian Z. HBsAg-specific CD8+ T cells as an indispensable trigger to induce murine hepatocellular carcinoma. Cell Mol Immunol 2021;18:128-37. [PMID: 31767976 DOI: 10.1038/s41423-019-0330-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Li L, Ye Y, Ran Y, Liu S, Tang Q, Liu Y, Liao X, Zhang J, Xiao G, Lu J, Zhang G, He Q, Hu S. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. Medicine (Baltimore) 2021;100:e25581. [PMID: 33907107 DOI: 10.1097/MD.0000000000025581] [Reference Citation Analysis]
78 Chen YY, Yeh MM. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation. J Formos Med Assoc 2021;120:68-77. [PMID: 32654868 DOI: 10.1016/j.jfma.2020.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
79 Cai Q, Gan C, Tang C, Wu H, Gao J. Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front Pharmacol 2021;12:784591. [PMID: 34887768 DOI: 10.3389/fphar.2021.784591] [Reference Citation Analysis]
80 van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ, Sonneveld MJ. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep 2021;3:100350. [PMID: 34557660 DOI: 10.1016/j.jhepr.2021.100350] [Reference Citation Analysis]
81 Nababan SHH, Mansjoer A, Fauzi A, Gani RA. Predictive scoring systems for in-hospital mortality due to acutely decompensated liver cirrhosis in Indonesia. BMC Gastroenterol 2021;21:392. [PMID: 34670501 DOI: 10.1186/s12876-021-01972-6] [Reference Citation Analysis]
82 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing Epidemiology of Hepatocellular Carcinoma in Asia. Liver Int 2022. [PMID: 35319165 DOI: 10.1111/liv.15251] [Reference Citation Analysis]
83 Hu Z, Su H, Zeng Y, Lin C, Guo Z, Zhong F, Jiang K, Yuan G, He S. Tetramethylpyrazine ameliorates hepatic fibrosis through autophagy-mediated inflammation. Biochem Cell Biol 2020;98:327-37. [PMID: 32383631 DOI: 10.1139/bcb-2019-0059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Saraya A. Deciding Among Noninvasive Tools for Predicting Varices Needing Treatment in Chronic Liver Disease: An Analysis of Asian Cohort. Am J Gastroenterol 2020;115:1650-6. [PMID: 32516202 DOI: 10.14309/ajg.0000000000000722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
85 Oku K, Hamijoyo L, Kasitanon N, Li MT, Navarra S, Morand E, Tanaka Y, Mok CC. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. Int J Rheum Dis 2021;24:880-95. [PMID: 33999518 DOI: 10.1111/1756-185X.14125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Sitbounlang P, Marchio A, Deharo E, Paboriboune P, Pineau P. The Threat of Multiple Liver Carcinogens in the Population of Laos: A Review. Livers 2021;1:49-59. [DOI: 10.3390/livers1010005] [Reference Citation Analysis]
87 Qu C, Wang Y, Wang P, Chen K, Wang M, Zeng H, Lu J, Song Q, Diplas BH, Tan D, Fan C, Guo Q, Zhu Z, Yin H, Jiang L, Chen X, Zhao H, He H, Li G, Bi X, Zhao X, Chen T, Tang H, Lv C, Wang D, Chen W, Zhou J, Cai J, Wang X, Wang S, Yan H, Zeng YX, Cavenee WK, Jiao Y. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci USA. 2019;116:6308-6312. [PMID: 30858324 DOI: 10.1073/pnas.1819799116] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
88 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 34.5] [Reference Citation Analysis]
89 Zeng S, Liu Y, Jiang C, Li B, Wen L, Feng Q. Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020;99:e22692. [PMID: 33031339 DOI: 10.1097/MD.0000000000022692] [Reference Citation Analysis]
90 Ye F, Huang W, Xue Y, Tang E, Wang M, Shi F, Wei D, Han Y, Chen P, Zhang X, Yu D. Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:285-300. [PMID: 33948441 DOI: 10.2147/JHC.S306966] [Reference Citation Analysis]
91 Li M, Chen L, Gao Y, Li M, Wang X, Qiang L, Wang X. Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. Liver Int 2020;40:2928-36. [PMID: 33025657 DOI: 10.1111/liv.14687] [Reference Citation Analysis]
92 Yi TT, Zhang HY, Liang H, Gong GZ, Cai Y. Betaine-assisted recombinase polymerase assay for rapid hepatitis B virus detection. Biotechnol Appl Biochem 2021;68:469-75. [PMID: 32388885 DOI: 10.1002/bab.1940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Zhang G, Tang F, Liang J, Wang P. Trajectories of middle-aged and elderly people's chronic diseases Disability Adjusted Life Years (DALYs): cohort, socio-economic status and gender disparities. Int J Equity Health 2021;20:179. [PMID: 34344369 DOI: 10.1186/s12939-021-01517-z] [Reference Citation Analysis]
94 Kabarra K, Golabi P, Younossi ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240-7. [PMID: 34486981 DOI: 10.1530/EC-21-0048] [Reference Citation Analysis]
95 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
96 Mu Q, Wang H, Tong L, Fang Q, Xiang M, Han L, Jin L, Yang J, Qian Z, Ning G, Zhang Y, Zhang Z. Betulinic acid improves nonalcoholic fatty liver disease through YY1/FAS signaling pathway. FASEB J 2020;34:13033-48. [PMID: 32777136 DOI: 10.1096/fj.202000546R] [Reference Citation Analysis]
97 Butt N, Ali Khan M, Rai L, Hussain Channa R, Khemani H, Abbasi A. Perception of Non-Alcoholic Fatty Liver Disease: Real-Life Experience From Pakistan. Cureus 2021;13:e16029. [PMID: 34336516 DOI: 10.7759/cureus.16029] [Reference Citation Analysis]
98 Lv X, Xiang X, Wu Y, Liu Y, Xu R, Xiang Q, Lai G. GATA binding protein 4 promotes the expression and transcription of hepatitis B virus by facilitating hepatocyte nuclear factor 4 alpha in vitro. Virol J 2021;18:196. [PMID: 34583732 DOI: 10.1186/s12985-021-01668-z] [Reference Citation Analysis]
99 Ramai D, Facciorusso A, Vigandt E, Schaf B, Saadedeen W, Chauhan A, di Nunzio S, Shah A, Giacomelli L, Sacco R. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells 2021;10:3401. [PMID: 34943908 DOI: 10.3390/cells10123401] [Reference Citation Analysis]
100 Wei L, Ding HG. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: What should we expect from a meta-analysis? Medicine (Baltimore) 2021;100:e26706. [PMID: 34397807 DOI: 10.1097/MD.0000000000026706] [Reference Citation Analysis]
101 Martínez-Uña M, López-Mancheño Y, Diéguez C, Fernández-Rojo MA, Novelle MG. Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. Int J Mol Sci 2020;21:E9368. [PMID: 33316927 DOI: 10.3390/ijms21249368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
102 Gani SA, Muhammad SA, Kura AU, Barahuie F, Hussein MZ, Fakurazi S. Effect of protocatechuic acid-layered double hydroxide nanoparticles on diethylnitrosamine/phenobarbital-induced hepatocellular carcinoma in mice. PLoS One 2019;14:e0217009. [PMID: 31141523 DOI: 10.1371/journal.pone.0217009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
103 Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf 2019;42:365-87. [PMID: 30343418 DOI: 10.1007/s40264-018-0743-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
104 Sun F, Yang F, Zheng S. Evaluation of the Liver Disease Information in Baidu Encyclopedia and Wikipedia: Longitudinal Study. J Med Internet Res 2021;23:e17680. [PMID: 33459597 DOI: 10.2196/17680] [Reference Citation Analysis]